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Abstract
Prion diseases are fatal neurodegenerative diseases of humans and animals characterized by gray matter spongiosis and
accumulation of aggregated, misfolded, protease-resistant prion protein (PrPres). PrPres can be deposited in brain in an
amyloid-form and/or non-amyloid form, and is derived from host-encoded protease-sensitive PrP (PrPsen), a protein
normally anchored to the plasma membrane by glycosylphosphatidylinositol (GPI). Previously, using heterozygous
transgenic mice expressing only anchorless PrP, we found that PrP anchoring to the cell membrane was required for typical
clinical scrapie. However, in the present experiments, using homozygous transgenic mice expressing two-fold more
anchorless PrP, scrapie infection induced a new fatal disease with unique clinical signs and altered neuropathology,
compared to non-transgenic mice expressing only anchored PrP. Brain tissue of transgenic mice had high amounts of
infectivity, and histopathology showed dense amyloid PrPres plaque deposits without gray matter spongiosis. In contrast,
infected non-transgenic mice had diffuse non-amyloid PrPres deposits with significant gray matter spongiosis. Brain graft
studies suggested that anchored PrPsen expression was required for gray matter spongiosis during prion infection.
Furthermore, electron and light microscopic studies in infected transgenic mice demonstrated several pathogenic processes
not seen in typical prion disease, including cerebral amyloid angiopathy and ultrastructural alterations in perivascular
neuropil. These findings were similar to certain human familial prion diseases as well as to non-prion human
neurodegenerative diseases, such as Alzheimer’s disease.
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Introduction
Transmissible spongiform encephalopathies (TSE diseases) or
prion diseases are fatal neurodegenerative diseases of humans and
animals. These diseases include scrapie in sheep, bovine
spongiform encephalopathy (BSE) in cattle, and chronic wasting
disease (CWD) in cervids, as well as several human diseases
including kuru, Gerstmann-Stra ¨ussler-Scheinker syndrome(GSS),
and sporadic, familial and variant forms of Creutzfeldt-Jakob
disease (CJD) (see [1] for review). TSE diseases are transmissible
within a species, but can also cross to new species in some cases.
For example, variant CJD appears to be a form of BSE
transmitted to humans. In addition, experimental transmission to
rodents such as mice, hamsters and, more recently, bank voles
[2,3], has provided numerous models for laboratory research.
In prion diseases brain pathology is characterized by spongiform
degeneration of the gray matter together with neuronal loss and
gliosis. During disease there is an accumulation in brain of an
abnormal partially protease-resistant form of prion protein
(PrPres) derived from host-encoded protease-sensitive prion
protein (PrPsen). PrPres can be detected by immunoblot or
immunohistochemistry, and this detection is often used as an
important diagnostic feature of prion disease. PrPres can be
deposited in brain either as large fibrillar amyloid plaques and/or
as small diffuse punctate deposits of non-amyloid aggregated
protein. The diffuse non-amyloid PrPres form is prevalent in many
human sCJD cases and most prion disease animal models [4–7].
However, both amyloid and non-amyloid forms of PrPres coexist
in some human and animal prion diseases [6] [8–13], and both
forms may contribute to prion disease pathogenesis.
A variety of proteins are capable of forming amyloid deposits in
nervous system tissues as well as other organs. Amyloid deposits
often displace organ structure resulting in dysfunction and cell
death. In cerebral amyloid angiopathy (CAA), associated with
Alzheimer’s disease (AD) and several genetic CNS amyloid
diseases, vascular amyloid deposits can damage the structure of
blood vessel walls leading to hemorrhage or thrombosis [14,15].
However, in AD, oligomeric pre-amyloid Aß aggregates are also
thought to have important neuropathogenic effects. For therapy of
diseases such as AD and prion diseases, where both amyloid and
PLoS Pathogens | www.plospathogens.org 1 March 2010 | Volume 6 | Issue 3 | e1000800non-amyloid may be pathogenic, it will be important to
understand the contribution of both types of abnormal protein
aggregates to the various pathogenic processes present in these
complex diseases. Therefore, we focused on the pathogenic effects
of PrPres amyloid versus non-amyloid induced by prion infection
in mice.
In uninfected animals PrPsen is anchored to the plasma
membrane by a glycosylphosphatidylinositol (GPI) moiety [16].
In prion disease PrPres is found on plasma membranes of neurons
and other brain cells, where it is associated with morphological
membrane changes that are common to different animal TSEs [7]
[17,18]. Membrane attachment of PrP may have an important
influence on the prion disease process. To study the role of PrP
membrane linkage on pathogenesis of prion disease we previously
generated 2 lines of transgenic mice (tg44+/2 and tg23+/2),
which express PrP lacking the GPI anchor at similar levels and do
not express GPI membrane–anchored PrP. Anchorless PrP in
these mice is secreted by cells and is not attached to the plasma
membrane [19]. After scrapie infection, both lines of transgenic
mice developed high titers of prion infectivity and extensive PrPres
amyloid deposits in brain at late times after infection; however,
typical scrapie clinical signs and gray matter spongiosis charac-
teristic of prion diseases were not seen [19].
In the present paper we studied homozygous anchorless PrP
transgenic mice, which expressed two-fold more anchorless PrPsen
than the above mentioned heterozygous transgenic mice. In these
experiments scrapie infection of homozygous mice produced a
fatal clinical disease. However, this disease differed in incubation
period, clinical signs, and neuropathology from typical prion
disease seen in non-transgenic mice, which express anchored PrP,
and thus appeared to be a distinct pathogenic process. Therefore,
depending on the presence or absence of anchored PrP, scrapie
infection could induce two different fatal brain diseases: PrPres
amyloidosis without gray matter spongiosis in anchorless PrP
transgenic mice, and diffuse non-amyloid PrPres with gray matter
spongiosis in mice with anchored PrP.
Results
Brain PrPsen levels in anchorless PrP transgenic mice and
non-transgenic mice
Since PrPsen expression is known to influence scrapie
incubation period [20] [21], it is possible that low PrP expression
might account in part for the lack of clinical scrapie disease in
previous experiments using heterozygous tg44+/2 and tg23+/2
mice [19]. Therefore, in the present study we generated
homozygous anchorless PrP transgenic mice from both lines 44
and 23. These mice each expressed two anchorless PrP transgene
alleles and no normal mouse PrP alleles.
PrPsen levels were analyzed by immunoblotting in brain
homogenates of uninfected transgenic and non-transgenic mice.
Homozygous tg44+/+ mice expressed 2-fold higher levels com-
pared to tg44+/2 mice (Figure 1A). Non-transgenic C57BL/10SnJ
micehomozygous for the PrP gene (Prnp+/+) were used as controls,
andthesemiceexpressed2-foldhigherPrPlevelsthan didPrnp+/2
mice(generated bycrossingPrnp+/+micetoPrnp-nullmicealsoon
the C57BL/10SnJ background (see methods)) (Figure 1A). Quan-
titative comparisons between transgenic and non-transgenic mice
were difficult due to PrP glycosylation differences (Figure 1A).
Therefore we compared these mice using PrPsen deglycosylated
with PNGase F (Figure 1B). In these experiments Prnp+/2 mice
had approximately four-fold higher PrPsen levels than tg44+/+
mice (compare lanes 2 vs. 4 and lanes 7 vs. 10). Given the 2-fold
difference between Prnp+/+ and +/2 mice, tg44+/+ expressed
8-fold lower levels of brain PrPsen than did Prnp+/+ mice. Brain
Figure 1. Brain PrPsen expression levels. C57BL/10 (Prnp+/+),
Prnp+/2, expressing normal anchored mouse PrP, and transgenic mice
(tg44+/+ and tg44+/2), expressing only anchorless mouse PrP were
compared. Immunoblots were done using brain homogenates made as
described in methods, and samples were serially diluted two-fold in
sample buffer to give the mg brain equivalents shown on the figure.
Bands were detected with monoclonal antibody D13. (A) No PNGase
digestion. Lanes 1–3: Prnp+/+, Lanes 4–6: Prnp+/2, Lanes 7–9: tg44+/+
and Lanes 10–12: tg44+/2. (B) After PNGase F treatment. Lanes 1–3:
Prnp+/2, Lanes 4–5: tg44+/+, Lanes 6–8: Prnp+/2 and 9–11: tg44+/+
mice. Lanes 1–5 were from one experiment and 6–11 were from a
separate experiment and results shown are for 4 different mice. Lower
apparent molecular weight in PrP of transgenic mice is due to lack of
the GPI anchor. Prnp+/2 mice appeared to have 4-fold more brain
PrPsen than tg44+/+ mice (compare lanes 2 and 4, also lanes 7 and 10).
Data shown are for tg44+/+ and tg44+/2 mice. By immunoblot PrPsen
expression levels in tg23 mice were indistinguishable from those in
tg44 mice (data not shown).
doi:10.1371/journal.ppat.1000800.g001
Author Summary
Prion diseases, also known as transmissible spongiform
encephalopathies, are infectious fatal neurodegenerative
diseases of humans and animals. A major feature of prion
diseases is the refolding and aggregation of a normal host
protein, prion protein (PrP), into a disease-associated form
which may contribute to brain damage. In uninfected
individuals, normal PrP is anchored to the outer cell
membrane by a sugar-phosphate-lipid linker molecule. In
the present report we show that prion infection of mice
expressing PrP lacking the anchor can result in a new type
of fatal neurodegenerative disease. This disease displays
mechanisms of damage to brain cells and brain blood
vessels found in Alzheimer’s disease and in familial amyloid
brain diseases. In contrast, the typical sponge-like brain
damage seen in prion diseases was not observed. These
results suggest that presence or absence of PrP membrane
anchoring can influence the type of neurodegeneration
seen after prion infection.
Anchorless Prion Protein
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(data not shown).
Scrapie-induced clinical disease in transgenic and non-
transgenic mice
Scrapie-induced clinical disease was analyzed in transgenic and
non-transgenic mice using two different scrapie strains, RML and
22L. After intracerebral (IC) inoculation of scrapie strain 22L,
Prnp+/+ and +/2 mice developed clinical scrapie at 150–165 dpi
and 245–260 dpi respectively (Figure 2A). Similar results were also
seen using the RML scrapie strain in Prnp+/+ mice (Figure 2B).
Prnp+/2 mice were not tested with the RML strain. In contrast to
experiments with non-transgenic mice, all tg44+/+ and tg23+/+
mice infected with strains 22L or RML developed neurological
signs and required euthanasia from 300 to 480 dpi (Figure 2).
Homozygous transgenic mice differed from non-transgenic mice in
incubation period, duration and progression of clinical signs, as
well as gait and postural abnormalities (Table 1). The most
obvious signs in homozygous transgenic mice were the presence of
a wide-based gait, rear extremity weakness with low posture, and
lack of kyphosis. The signs seen in homozygous transgenic mice
differed from the narrow-based tippy-toed gait and frequent
kyphosis seen in infected Prnp+/+ and +/2 mice (Table 1). The
gait and postural differences probably reflected different patterns
of neurological damage. Overall the differences between non-
transgenic mice and homozygous transgenic mice suggested that
there might be different pathogenic mechanisms operating in these
two scrapie-induced disease models.
In our earlier studies, heterozygous tg44+/2 and tg23+/2 mice
did not manifest the usual clinical signs of scrapie during 600 days of
observation after infection with scrapie strains 22L or RML (Table 1)
[19]. However, in the present experiments with the experience of
observing the clinical signs described above in homozygous
transgenic mice, we noted similar clinical signs in the infected
heterozygous transgenic mice starting around 480 dpi. Clinical
diagnosis in these mice was difficult due the erratic presence of signs
in the initial stages, the longer duration of signs, and the possibility of
confusion with signs of old age. These mice were euthanized between
480 and 700 dpi, but the indication for euthanasia was primarily
debilitation (weight loss, dermatitis, bladder distention, cancer and
infections), rather than neuromuscular dysfunction.
PrPres levels
PrPres deposition in brain is a major hallmark of prion diseases,
and PrPres is often associated with areas of brain degeneration.
Therefore brain PrPres levels in scrapie-infected mice were analyzed
by immunoblot. As shown in Figure 3, tg44+/+ mice with clinical
neurological disease had higher amounts of PrPres at 348–408 dpi
than tg44+/2 mice had at 567–594 dpi, which was when these mice
had to be euthanized due to debilitating signs as described in Table 1.
A similar difference was seen between tg23+/+ and tg23+/2 mice
(data not shown). The difference between tg44+/+ and tg44+/2
mice in timing and levels of PrPres correlated with the higher PrPsen
expression level seen in homozygous mice (Figure 1A), and appeared
to explain the earlier onset and more prominent clinical signs seen in
homozygous transgenic mice.
Figure 2. Survival curves for scrapie-infected mice. Transgenic
mice (tg44+/+ and tg23+/+) expressing only anchorless PrP, C57BL/10
(Prnp+/+) and Prnp+/2 mice, expressing normal anchored mouse PrP
were compared. Mice were inoculated intracerebrally with 22L scrapie
(panel A) and RML scrapie (panel B) and observed weekly for
development of disease (see Table 1). Mice were euthanized when
clinical signs were severe as described in Table 1. N values for each
group are as follows: Panel A (22L): Prnp+/+, 11; Prnp+/2, 17; tg44+/+,
23; tg23+/+, 10. Panel B (RML): Prnp+/+, 8; tg44+/+, 21; tg23+/+,9 .
doi:10.1371/journal.ppat.1000800.g002
Table 1. Clinical aspects of disease in 22L or RML scrapie-
infected C57BL/10 and tg44+/+ mice.
Clinical Manifestations C57BL/10 Tg44+/+
a
Incubation period (days) 150–160 300–480
Duration of clinical signs (days) 15–25 30–60
Progression of signs steady erratic
b
Kyphosis most
c few
c
Narrow-based tip-toe gait most few
Splayed hind legs, wobbly gait few most
Low body posture few most
Weight loss all all
Ungroomed coat all all
Hypoactive (late) all all
Rear leg clasping response most most
aClinical signs were similar in infected tg44+/+ and tg23+/+ mice infected by IC
inoculation with either 22L or RML scrapie strains as described in the methods.
End-stage neurological disease in these mice was characterized by profound
weakness, hypoactivity and reduced ability to eat or drink, requiring
euthanasia. In heterozygous tg44+/2 and tg23+/2 mice clinical signs were
similar, but less severe and more erratic. However, most heterozygous mice
developed dermatitis, bladder distention, infection and tumors requiring
euthanasia prior to development of end-stage neurological disease.
bClinical signs were present on an erratic basis initially, but became more
consistent and severe over time.
cMost=85–100%; few=0–15%.
doi:10.1371/journal.ppat.1000800.t001
Anchorless Prion Protein
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weight of 19 kD. In our earlier study this band was found to react
with an anti-PrP peptide antibody (R20) directed at the C-terminal
region of PrP (residues 218–232) [19]. Therefore, there was no
evidence for loss of these C-terminal residues as often occurs in
human GSS [6,22].
Interestingly tg44+/+ and tg44+/2 mice had higher PrPres levels
than did non-transgenic Prnp+/+ or +/2 mice, but the non-
transgenic mice died earlier than the tg44+/+ mice (Figure 2). This
suggested either that amyloid PrPres in tg44+/+ mice might be less
pathogenic than the non-amyloid PrPres in non-transgenic mice, or
that transgenic mice might be less susceptibleto the pathogenic effects
of PrPres amyloid due to the absence of membrane-anchored PrP.
Infectivity levels in tg44 mice
Previously we showed that scrapie-infected tg44+/2 mice
lacked signs of clinical scrapie but had infectivity titers in brain as
high as 4.6610
8 ID50/gram brain at 120–286 dpi as measured by
end-point titration in C57BL/10 mice [19]. In the present
experiments we passaged brain from infected tg44+/2 (passage
1) mice into other tg44+/2 mice (passage 2), and at 512 and
531 dpi we found brain infectivity titers of 1.1–1.3610
10 ID50/
gram brain (Table 2). These mice also had brain PrPres levels
similar to those shown in other tg44+/2 mice (Figure 3). Similar
high titers were detected in passage 1 homozygous tg44+/+ mice
at 384 dpi (Table 2). Thus in the transgenic anchorless PrP model,
scrapie infectivity was present in brain at very high titers.
Furthermore, the agent did not appear to develop new strain-
like properties selective for tg44+/2 mice as it could passage easily
from tg44+/2 mice to either C57BL/10 or tg44+/2 mice.
Histopathology and PrPres distribution detected by IHC
We compared the PrPres deposition and neuropathology after
scrapie infection in transgenic tg44+/+ mice and non-transgenic
C57BL/10 control mice (Table 3). Following scrapie infection in
C57BL/10 mice typical TSE-specific diffuse deposits of PrPres
were found in many brain areas (Figure 4A, 4B). This PrPres did
not stain with the amyloid stain, Thioflavin S [19]. In many brain
regions by H&E staining we observed gray matter spongiosis
(Figure 4C), which is an important feature of TSE/prion diseases.
In scrapie-infected tg44+/+ mice PrPres accumulated as large
dense plaque-like deposits, usually in a perivascular location
around capillaries, veins and arteries in numerous brain regions,
including leptomeninges, cerebral cortex, corpus callosum,
forebrain, hippocampus, thalamus, hypothalamus, midbrain,
colliculi, brainstem, and spinal cord (Figure 4D, 4E, 5A, 5B) After
infection with the 22L scrapie strain, the cerebellar molecular layer
and granular layer were also involved [19], but this was not seen
after infection with the RML strain (Figure 4D). These deposits
were Thioflavin S-positive [19], and no areas of diffuse non-
amyloid PrPres were observed. The most distinguishing histo-
pathological feature in tg44+/+ mice at the time of clinical signs
was distortion of brain structures adjacent to large amyloid plaques
in many areas (Figures 4D, E, H–L). These areas had intense
micro- and astrogliosis (Figures 4G). Small blood vessels showed
occasional micro-hemorrhages, or perivascular haemosiderin
accumulation, but no lymphocyte infiltration of blood vessel walls
was detected. Marked neuronal loss was seen around edges of
some gray matter plaques (Figure 4H, I); however, no gray matter
spongiosis typical of prion diseases was seen (Figure 4C vs 4F). In
addition, tg44+/+ mice had focal areas of abnormal staining of
amyloid precursor protein (APP) (Figure 4K), non-phosphorylated
neurofilament protein (NFP) (Figure 4L), and phosphorylated NFP
(not shown), all of which indicated a process of severe axonal
dystrophy. These latter effects were rarely seen in scrapie-infected
C57BL/10 mice (Table 3). These results suggested that scrapie-
infected anchorless PrP transgenic mice had a different pathogenic
process compared to non-transgenic C57BL/10 mice.
Ultrastructural analysis of brain from infected tg44+/+
mice
For higher resolution of details, scrapie-infected tg44+/+ mice
were also studied using immunohistochemistry on 1 micron thick
plastic-embedded sections as well as immunogold labeling at the
Figure 3. Detection of PrPres by immunoblot using monoclonal
antibody D13. Comparison of PrPres in brain of 22L scrapie-infected
tg44+/+ and tg44+/2 mice at the time of clinical disease. All lanes were
loaded with 0.25 mg brain tissue equivalents. A clinical Prnp+/2 mouse
is shown for comparison. Lane 1: Prnp+/2 (251 dpi), PrPres bands are
seen at 21, 28, and 31 kD; lanes 2–5: tg44+/2 mice (567, 589, 594,
594 dpi) and lanes 6–9 tg44+/+ (348, 365, 384, 408 dpi). PrPres bands
are at 18 and 23 kD. The sizes are lower in these mice due to lack most
carbohydrates and lack of GPI [19]. PrPres levels in tg44+/2 mice were
approximately 50% lower than in tg44+/+ mice.
doi:10.1371/journal.ppat.1000800.g003
Table 2. Infectivity titers of 22L scrapie from brains of Tg44
mice after 1 or 2 passages.
Tg44 zygosity
a Passage
b Days
c Titer
d
+/2 1 286 1.1610
9
+/2 2 512–531 1.1–6.3610
10
+/+ 13 8 4 .1610
9e
aZygosity of tg44 transgene in scrapie-infected mouse whose brain infectivity
was titered.
bNumber of passages in tg44 mice (1=first; 2=second). For passage 1, tg44+/2
and tg44+/+ mice were inoculated intracerebrally with a 22L scrapie stock
derived from C57BL/10 mice with a titer of 1.4610
9 ID50per gram of brain
tissue. For the second passage in tg44+/2 the brain of the 286 dpi passage 1
tg44+/2 mouse was used as the inoculum. The preliminary titration of the
passage 1 mouse from 286 dpi was previously reported to be .2.4610
8
ID50per brain [19].
cDays post-inoculation when brain was harvested for titration.
dBrain titer was determined by end-point dilution titration in C57BL/10 mice for
tg44+/2 or in tga20 mice for tg44+/+. Titer was expressed as ID50per gram of
brain tissue.
eThe titration of this brain is still in progress.
doi:10.1371/journal.ppat.1000800.t002
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both perivascular and vascular PrPres labeling (Figure 5A), as well
as occlusion of vessels in some cases (Figure 5B). By electron
microscopy abundant PrPres labeling of blood vessels was seen
most predominantly at basement membranes. In some larger
vessels smooth muscle cells of the media were atrophied and
replaced by extensive PrPres accumulation (Figure 5C). Vascular
and plaque PrPres accumulation could be seen to be of a fibrillar
amyloid nature at high magnification (Figure 5D). In smaller
vessels PrPres was seen at both endothelial and pericyte basement
membranes (Figure 5E). PrPres was also observed within the
extracellular space along the borders of swollen astroglial and
neurite processes in the absence of visible fibrillar amyloid
(Figure 5F and G). No PrPres labeling was seen in uninfected
control mice.
Using staining with uranyl acetate/lead citrate large areas of
distended swollen processes could be seen (Figure 6A), which were
similar to the areas of immunogold-labeled PrPres shown above
(Figure 5G). At higher magnification swollen perivascular glial
processes were often seen (Figure 6B), and fibrils were visible in the
endothelial basement membrane (Figure 6C) and/or pericyte
basement membrane (Figure 6D). The initial site of aggregation
into fibrils was in the ablumenal basement membranes (Figure 5D).
Dystrophic neurites were also frequently noted in gray matter
(Figure 6E). These were most conspicuous surrounding perivas-
cular amyloid plaques and corresponded to sites of APP labeling.
In white matter we observed degeneration of axons, including
empty distended myelin sheaths (Figure 6F) (Table 3) which could
be seen as white matter vacuoles by light microscopy (Figure 4F).
In contrast to transgenic mice, infected C57BL/10 mice at the
time of clinical disease had numerous TSE vacuoles with broken
or ‘‘hanging’’ membranes (not shown) [23] [24]. Such vacuoles
were never seen in infected transgenic mice (Table 3). In C57BL/
10 mice other ultrastructural hallmarks specific for classical prion
diseases including membrane accumulation of disease-specific
PrPres and TSE-specific membrane alterations were also seen, as
reported previously in other prion disease models [17] [7,18,24]
(Table 3). However, none of these prion disease-specific features
was seen in infected tg44+/+ mice. The ultrastructural differences
between scrapie-infected C57BL/10 and tg44+/+ mice supported
the conclusion that the pathogenesis of disease in these transgenic
mice was not typical TSE/prion disease.
Brain graft experiments
The reasons for the different types of scrapie-induced
pathogenesis in C57BL/10 mice and anchorless PrP transgenic
mice are not known. Two possibilities include: first, PrPres
amyloid and diffuse non-amyloid PrPres might have different
neurotoxic effects; second, PrPsen anchoring might influence
neurotoxicity induced by infection.
Table 3. Comparison of histopathological features in scrapie-infected C57BL/10 mice and homozygous anchorless PrP transgenic
mice (tg44+/+).
Method Lesion TSE-specific C57BL/10 mice Tg44+/+ mice
Light microscopy Protease-resistant PrP
a yes fine
b coarse
b
PrP amyloid (Thioflavin S)
b yes no yes
Distortion of brain by amyloid
c no no yes
White matter vacuoles no rare yes
APP upregulation (a-APP)
d no rare yes
Axonal dystrophy (a-NFP)
d no rare yes
Neuronal loss no yes yes
Astrogliosis & microgliosis no yes yes
Gray matter vacuoles
e no yes rare
Electron microscopy Membrane abnormalities
f yes yes no
Dystrophic neurites and axons no rare yes
Neuritic and glial swelling no rare yes
Degenerate myelinated processes
g no rare yes
aPartially protease-resistant PrP (PrPres) is a hallmark of TSE/prion diseases. Most researchers including ourselves rely on the correlation between the immunoblot
detection of PrPres and the immunohistochemical detection of PrP with staining properties and regional distribution found only in prion-infected animals, and thus
refer to such disease-associated PrP as PrPres or PrPd.
bIn most mouse scrapie models PrPres has a diffuse fine punctate staining pattern which is negative for staining with the amyloid stain, Thioflavin S. In both
homozygous and heterozygous anchorless PrP transgenic mice the PrPres has a coarse dense plaque-like staining pattern and is Thioflavin S-positive.
cDistortion of neuroanatomical features such as the hippocampal and cerebrocortical neuronal layers was associated with the presences of large PrPres amyloid
plaques. Such distortion was accompanied by neuronal loss (Figure 4H–L). This feature was seen in tg44+/+ and tg23+/+ mice, but was less frequent in heterozygous
transgenic mice. Brain distortion appeared to be the result of the large amounts of PrPres amyloid present in homozygous transgenic mice (Figure 3).
dAbnormal staining with anti-APP indicates axonal or neuronal damage. This is easily seen in infected tg44+/+ mice, but is minimal in infected C57BL/10 mice.
Antibodies reactive with phosphorylated or non-phosphorylated neurofilament protein (NFP) both showed abnormal staining in infected tg44+/+ mice compared to
C57BL/10 mice (Figure 4L vs 4M).
eTSE vacuoles in gray matter are a hallmark of classical prion diseases. At the ultrastructural level they are characterized by fragmentation of the inner limiting
membrane and presence of membrane fragments hanging into the vacuole, and by electron microscopy PrPres detectable by immunogold labeling is not found to be
colocalized with these vacuoles ([13], [17], [7]).
fSeveral ultrastructural abnormalities, including spiral membranes, invaginated membranes, increased and fused clathrin-coated pits and membrane microfolds, have
been found to be unique to TSE diseases, all of which co-localize with disease-associated membrane accumulations of PrPres. These changes are present in mice
infected with different murine scrapie strains [17], in sheep scrapie [18] and in cattle BSE [7], and were not seen in infected homozygous or heterozygous tg44 or tg23
mice.
gIn white matter distended empty myelin sheaths were seen, and these were often large enough to be noted as ‘‘vacuoles’’ by light microscopy.
doi:10.1371/journal.ppat.1000800.t003
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PLoS Pathogens | www.plospathogens.org 5 March 2010 | Volume 6 | Issue 3 | e1000800Figure 4. Light microscopic histopathology of scrapie-infected C57BL/10 and tg44+/+ transgenic mice. (A) Whole brain sagittal section
of C57BL/10 mouse infected IV with RML scrapie at 180 dpi showing wide distribution of diffuse PrPres stained with monoclonal antibody D13. (B)
High power view of C57BL/10 mouse infected IC with RML scrapie at 157 dpi showing diffuse punctuate pattern of PrPres in hippocampus. (C) H&E
stain of forebrain of C57BL/10 mouse infected IP with 22L scrapie at 375 dpi. Anterior commissure white matter (WM) is seen in lower right.
Numerous scrapie vacuoles (arrows) are visible in surrounding gray matter(GM). (D) Whole brain saggital section of tg44+/+ mouse D554 infected IC
with RML scrapie showing dense plaque-like PrPres stained with monoclonal antibody D13 at 341 dpi. PrPres was found in most CNS areas including
cerebral cortex, corpus callosum, forebrain, hippocampus, thalamus, hypothalamus, midbrain, colliculi, brainstem, and spinal cord. Cerebellar
involvement was minimal after RML infection, as shown in panel 4D, but was strong in cerebellar molecular layer, granular layer and meninges after
22L infection (not shown). (E) Higher power of panel D shows large dense PrP plaques surrounding dentate gyrus of hippocampus often in a
perivascular distribution (arrows). Note difference compared to diffuse PrPres staining in panel B. (F) H&E stain of mouse D554 showing vacuoles in
the white matter (WM) near the anterior commissure and no vacuoles in surrounding gray matter, i.e. opposite distribution of vacuoles compared to
C57BL/10 mouse in panel C. (G) Astrogliosis seen by staining with anti-GFAP in dentate gyrus of mouse D554. (H) H&E stain of dentate gyrus of mouse
D554 shows marked neuronal loss in lower arm of gyrus (box and arrow). Boxed outlines region shown in panel I. (I) High power view of lower arm of
dentate gyrus outlined in panel H, shows multiple areas of neuronal loss (arrows). Plaques surround this area and one plaque is indicated with the
arrowhead at the left. (J) High power view of area shown in panel I shows D13 staining of PrPres plaques impinging on damaged neurons of the
dentate gyrus (arrow). Arrowhead shows plaque around blood vessel in upper left corner. (K) Deposition of amyloid precursor protein, APP, (red-
brown stain) adjacent to area of neuronal loss (arrows) in dentate gyrus of same area shown in panels I and J. (L) Abnormal axonal proliferation
shown by staining with anti-neurofilament protein in area of neuronal loss (arrows) in dentate gyrus of mouse D554. (M) Anti- neurofilament pro-
tein staining of dentate gyrus of uninfected control mouse shows no neuronal damage or abnormal axonal staining within the gyrus. Scale bars in
panels B, E, G, and H are 100 microns; all other scale bars are 50 microns. Similar pathological changes were seen at the time of clinical disease in both
tg44+/+ and tg23+/+ mice infected with either 22L or RML strains of scrapie. D13 staining of PrPres in panels E and J was similar to results described
previously in tg44+/2 and tg23+/2 mice at $498 dpi [19].
doi:10.1371/journal.ppat.1000800.g004
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PLoS Pathogens | www.plospathogens.org 6 March 2010 | Volume 6 | Issue 3 | e1000800Figure 5. Immunological detection of PrPres in brain at both light and electron microscopic levels. The 22L scrapie-infected anchorless
PrP tg44+/+ mouse shown was clinically positive at 377 dpi. (A–B) Light microscopy of 1 mm thick plastic-embedded tissue labelled with monoclonal
antibody 1A8. (A) shows intravascular and perivascular PrPres. In (B), the marked vascular amyloid infiltration is associated with occlusion of the
vascular lumen (boxes indicate occluded lumens of two vessels). When these vessels were visualised in the electron microscope the smooth muscle
of the vascular media was totally replaced by amyloid and an amorphous electron dense material filled the lumen (not shown). (C–F) Electron
microscopy. (C) Low power view of large PrPres amyloid plaque adjacent to a small artery. Vessel lumen is in upper left corner and an endothelial cell
with a prominent nucleus is to the right of the lumen. Silver enhanced gold-labeled PrPres is seen within the basement membrane (BM) and within
the heavy amyloid accumulation which partially replaces the smooth muscle media layer. Amyloid bundles radiate away from the vessel and through
the neuropil at the bottom right. (D) A high magnification illustration of (C) showing PrPres labelling on small bundles of amyloid fibrils at the
periphery of the plaque. (E) Marked PrPres accumulation at the endothelial and pericyte basement membranes (arrows) and extending into narrow
extracellular spces between nearby neurites and perivascular glial processes. Asterix (*) shows area of astrocytic cytoplasmic swelling. Lu; lumen. (F)
Neuropil of cerebrum showing immunogold label for PrPres present over the extracellular spaces between neurites bounded by pairs of adjacent
plasmalemmae. No visible amyloid fibrils were visible and the spaces between cellular processes were regular and even. This non-fibrillar PrPres
labelling which dissects between neurite and glial cell profiles may extend over large area of neuropil as shown in (G). Asterix (*) on left side shows
enlarged glial process with loss of normal cytoplasmic organelles. Similar findings were observed in tg44+/+, tg44+/2 and tg23+/2 mice. Tg23+/+
mice were not examined by electron microscopy. Scale bars: A and B, 20 mm; C and D, 1 mm; E and G, 2 mm; F, 500 nm.
doi:10.1371/journal.ppat.1000800.g005
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could induce gray matter vacuoles in tissue expressing anchorless
PrPsen, brain tissue from C57BL/6 mice at embryonic day E12–
E14, which expressed green fluorescent protein constitutively in all
tissues [25], was grafted into the brain of adult tg44+/2 mice or
PrP null mice as controls [26]. One month after grafting, mice
were infected IC with scrapie, and at 132–511 dpi the brain tissue
was examined by histopathology. Recipients had from 1–6
detectable grafts per mouse (Table 4). Representative grafts are
shown in Figure 7.
At 261 dpi in the control PrPnull recipient, C57BL/6 graft
tissue, identified by presence of green fluorescent protein (GFP)
(Figure 7A), had easily detectable PrPres (Figure 7B) present both
within the graft and at the interface between the graft and the host
tissue, but PrPres did not appear to spread extensively into the
PrPnull tissue. TSE gray matter vacuolation was seen only within
Figure 6. Ultrastructure of cerebral cortex and cerebellum of a 22L scrapie-infected tg44+/+ mouse. Sections were from same mouse as
shown in Figure 5, and were stained with uranyl acetate/lead citrate. (A) Area of neuropil with severe vacuolation where most vacuoles originate
within processes and are separated from each other by intact membranes. (B) Several distended astrocytic processes (asterisks) of the perivascular
glial limitans are present around a blood vessel Lu: lumen. (C) On higher magnification of boxed area from (B), the endothelial basement is shown to
be filled with irregularly orientated amyloid fibrils (arrows). (D) The earliest stage of vascular amyloid is shown. Here the endothelial basement
membrane (black arrowheads) is intact, but the pericyte basement membrane (black arrows) is thickened and heavily infiltrated with short amyloid
fibrils (white arrowheads). (E) Severe neuritic dystrophy in which several processes show an excessive accumulation of organelles and abnormal
electron dense bodies. (F) White matter of the cerebellum showing an empty myelin sheath (seen as vacuoles by light microscopy) and also a dark
degenerate axon (asterisk) within an intact myelin sheath. Similar findings were observed in RML scrapie-infected tg44+/+ mice. Scale bars: A, 2 mm; B,
E, F, 1 mm; C, 500 nm; D, 500 nm.
doi:10.1371/journal.ppat.1000800.g006
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report [26].
In tg44+/2 recipient mice receiving C57BL/6 grafts, PrPres
and gray matter vacuolation was also seen in the graft (Figure 7F
and 7I). In the adjacent host tissue expressing anchorless PrP,
amyloid PrPres and white matter vacuoles were noted; however,
the C57BL/6 PrPres present at the edges of the graft appeared to
be unable to induce gray matter vacuoles in the adjacent
transgenic tissue (Figure 7F). In some cases the graft cells were
not well-demarcated from the host (Figure 7G), and it was not
clear whether the PrPres and vacuoles were in the graft or the host
(Figure 7H and 7I). These results were representative of
observations in 25 grafts in tg44+/2 recipients where PrPres
was detected in the graft (Table 4). In summary, we found no
grafts where expression of anchored PrPres from the C57BL/6
graft could be associated with gray matter spongiosis in adjacent
transgenic host tissue. This result suggested that expression of
anchored PrPsen in gray matter might be a fundamental
requirement for the induction of the typical TSE/prion disease
pathogenic process.
Discussion
In the present experiments scrapie infection of transgenic mice
expressing anchorless PrP resulted in a slow fatal brain disease.
These results demonstrated new mechanisms of prion-induced
pathogenesis associated with the presence of PrPres amyloid and
the absence of GPI-anchored PrP. This disease lacked gray matter
spongiosis and differed in this respect from scrapie infection in
non-transgenic mice, where the disease is characterized by
extensive gray matter spongiosis and non-amyloid PrPres
deposition.
The current results raised the question of how lack of GPI-
linked membrane anchoring of PrP might facilitate formation of
PrPres amyloid. GPI anchorless PrP has a longer biological half-
life [27] and is secreted by the cell. Both of these attributes might
allow more effective and extensive interactions between soluble
PrP molecules. In addition, the minimal amount of carbohydrates
and the absence of the GPI group on anchorless PrP might favor
amyloidogenic hydrophobic protein-protein interactions, particu-
larly at a time of partial protein unfolding during PrP conversion.
These features of anchorless PrP are likely to contribute to its
enhanced tendency to form amyloid during conversion to PrPres.
Anchorless protease-resistant PrP, cleaved at residue 228,
comprises 15% of the PrPres in hamster scrapie brain extracts
[28], but it is unclear whether this material contributes to the
amyloid PrP seen in this model.
Our results differed from those of two interesting mouse prion
disease models where PrPres was also found almost entirely in an
amyloid form. In the GSS PrP-8kd model [29] and the G3-ME7
model [30], which both used PrP mutant mice, PrP amyloid was
seen primarily in the corpus callosum, but did not spread
significantly to other brain regions. There was no clinical disease
in these models, and transmission experiments suggested very low
infectivity titers in the GSS PrP-8kd model. Compared to these
two models, the three main distinguishing features of the
anchorless PrP model are the ability of the PrPres amyloid to
accumulate widely throughout the brain (Figure 4), the resulting
fatal brain disease (Figure 2), and the high titer of transmissible
agent (Table 2) [31].
The association of amyloid deposition without gray matter
spongiosis in our system is reminiscent of the neuropathology seen
in certain human familial prion diseases. For example, GSS
patients with PrP mutations Y145Stop and Y163Stop had both
CAA and parenchymal perivascular amyloid without gray matter
spongiosis [32] [33]. Both these mutations result in C-terminally
truncated PrP lacking the GPI anchor. Parenchymal amyloid
deposition without gray matter spongiosis has also been seen in
GSS patients with several other PrP mutations including P102L,
P105L, A117V and F198S [6]. Recently two human GSS patients
with new PrP mutations producing nonsense codons at positions
226 and 227 were described [34]. Both patients had widespread
PrPres amyloid deposition in the absence of gray matter
spongiosis, and one had CAA. These patients expressed a nearly
full-length form of PrP lacking 6–7 C-terminal residues and the
GPI anchor, which was quite similar to the PrP expressed in our
anchorless PrP tg mice.
In many GSS patients, amyloid PrPres purified from brain was
truncated resulting in a 7–11 kDa protease-resistant fragment
from the central region of PrP (approximately residues 81–
150)[6,22,34]. Interestingly, presence of this truncation has been
correlated with the lack of gray matter spongiosis [8,9]. In
contrast, based on previous immunoblot studies, the proteinase K-
resistant PrPres amyloid in our model appeared to contain residues
88–231 [19], which was similar to the PrPres found in human and
animal prion diseases with extensive gray matter spongiosis.
Furthermore, PrPres in tissue sections could be stained with anti-
PrP serum R24, specific to residues 23–37 (data not shown)
suggesting that there was no significant truncation at the N-
terminus beyond the signal peptide. Thus, lack of spongiosis in our
model appeared dependent on the absence of GPI-anchoring
rather than truncation of the PrPres.
Two possibilities might explain the correlation between lack of
GPI- anchored PrP and lack of gray matter spongiosis in our
infected transgenic mice: (1) anchorless amyloid PrPres might be
less neurotoxic than diffuse PrPres, and/or (2) anchored PrPsen
might be required for PrPres-mediated neurotoxic membrane
interactions. The former explanation could not be proven or
excluded by our results. However, the latter interpretation was
supported by data from brain graft experiments. After scrapie
infection of tg44+/2 mice grafted with C57BL/6 brain expressing
normal anchored PrPsen, we observed gray matter spongiosis and
non-amyloid PrPres deposition in C57BL/6 grafts, but not in
Table 4. Studies of PrPres and gray matter vacuolation in
scrapie-infected anchorless PrP tg44+/2 mice with C57BL/6
embryonic brain grafts.
Recipient host genotype
PrPnull Tg44+/2
Number of mice 7 10
Number of grafts 20 31
Grafts with PrPres 20 25
Grafts with gray matter vacuoles 18 22
Adjacent host gray matter with
PrPres
02 0
Adjacent host gray matter with
vacuoles
00
Anchorless PrP tg44+/2 mice or PrPnull (2/2) adult mice were grafted with
12–14 d embryonic brain tissue from C57BL/6 mice expressing normal
anchored PrP and green fluorescent protein (GFP) [25], as described in the
Methods. One month after grafting, mice were infected with scrapie by IC
inoculation. Mice were euthanized at various times from 135–511 dpi, and brain
tissue sections were examined by H&E staining and immunohistochemical
staining for GFP and PrPres.
doi:10.1371/journal.ppat.1000800.t004
Anchorless Prion Protein
PLoS Pathogens | www.plospathogens.org 9 March 2010 | Volume 6 | Issue 3 | e1000800adjacent host tissue expressing only anchorless PrPsen. Tissue
expressing only anchorless PrPsen appeared to be unable to
respond to the presence of GPI-anchored PrPres produced in the
nearby grafts, and no gray matter spongiosis was produced.
Therefore, lack of anchored PrPsen might by itself explain the lack
of gray matter spongiosis in transgenic mice.
However, even in the absence of anchored PrPsen, the amyloid
PrPres was able to induce additional pathogenic processes capable of
causing fatal neurological disease. By both light and electron
microscopy we observed evidence for three distinct pathogenic
processes not seen in typical prion disease in C57BL/10 mice (Box 1):
(1) Brain damage caused by tissue distortion by large amyloid
plaques. These plaques were associated with neuronal loss, axonal
pathology and gliosis (Figure 4E, H–L Figure 6A,E,F). The more
rapid accumulation of PrPres in tg44+/+ mice compared to
tg44+/2 mice (Figure 3) suggested a faster growth of large space-
occupying plaques which might explain in part the clinical
neurological signs leading to death of tg44+/+ and tg23+/+ mice
(Figure 2).
(2) A second pathogenic process in scrapie-infected transgenic
mice was suggested by ultrastructural studies finding that the early
aggregation of PrPres into fibrillar amyloid was located at or
Figure 7. Detection of PrPres and vacuolation in brain tissue of PrPnull and tg44+/2 mice with C57BL/6 brain grafts. Grafts expressed
green fluorescent protein (GFP), and mice were infected IC with 22L scrapie approximately 5 weeks after grafting. Panels A–C, PrPnull recipient at
261 dpi; Panels D–F, tg44+/2 recipient at 261 dpi; Panels G–I, tg44+/2 recipient at 200 dpi. Panels A, D, G show staining with anti- GFP which
detects constitutive GFP expression in the C57BL/6 donor tissue. Panels B, E, H show D13 staining of PrPres. Panels C, F, I show H&E staining to detect
scrapie-induced vacuoles indicated by arrows.
doi:10.1371/journal.ppat.1000800.g007
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This was associated with vascular damage including occlusion
(Figure 5B), amyloid replacement of basement membrane and
tunica media, and occasional micro-hemorrhages. This pathology
was similar to that observed in CAA seen in Alzheimer’s disease
and several familial amyloid diseases including two prion diseases
[14,15,32,33].
(3) Evidence of a third pathogenic process in the transgenic mice
was suggested by finding of small deposits of immunogold-labeled
PrPres at the ultrastructural level in the extracellular spaces
between glial and neuritic processes in gray matter (Figures 5D,
5E, 5F). These PrPres deposits were small, and there was no
distortion of the extracellular space or visible aggregation into
amyloid fibrils. However, the adjacent processes were often highly
dystrophic (Figure 6E) or swollen and devoid of organelles, and
they appeared to coalesce to form empty spaces larger than the
original processes (Figures 5G, 6A, 6B). These abnormal areas,
which were also noted in heterozygous tg44+/2 and tg23+/2
mice, appeared to represent a form of damage related to small,
rather than large, PrPres deposits, and they did not require the
presence of anchored PrPsen for their formation.
The early localization of PrPres at basement membranes
(Figures 5A, C, D), suggested that the PrP conversion process
might initiate at these sites, and implied that basement membrane
molecules might facilitate PrP conversion. For example, basement
membrane might filter or trap soluble PrPsen molecules or small
PrPres oligomers from the extracellular interstitial fluid of brain
increasing their local concentration, thus favoring conversion to
larger PrPres amyloid aggregates. Serum amyloid P-component
which binds to all amyloids and is a constituent of basement
membranes might also contribute to local PrP conversion [35]. In
addition, collagen, laminin and heparin sulfate-containing proteo-
glycans are major components of basement membranes, and PrP
can bind to both the laminin receptor and heparan sulfate which
can associate directly or indirectly with PrP [36–38]. Heparan
sulfate and other glycosaminoglycan (GAG) moieties can delay
scrapie disease in vivo [39–42] [43,44], and some GAG molecules
can alter PrP conversion in vitro [45]. A scaffolding mechanism
might account for this effect. For example, soluble anchorless
PrPsen monomers might be held in place by GAG polymers to
increase local concentration and facilitate conversion by PrPres,
analogous to the tethering of anchored PrPsen on cell membranes
[46,47]. In addition, attachment of small mobile PrPres oligomers
to GAG polymers might assist conversion at the basement
membrane. Subsequently newly formed larger less mobile PrPres
could serve as an efficient scaffold for further conversion allowing
the process to extend out into the brain parenchyma. Eventually
this process might form very large PrPres amyloid plaques with
blood vessels at the center as we observed (Figure 4E and 5A).
The vascular amyloid pathology seen in our scrapie-infected
transgenic mice (Figures 4E, 5A–D, 6B–D) was similar to CAA
seen in Alzheimer’s disease as well as several familial amyloid
diseases [14], including two forms of familial prion disease [32]
[14]. In Alzheimer’s disease, amyloid fibrils within vascular
basement membranes are thought to impede interstitial fluid
drainage leading to an increase in Ab concentrations within the
extracellular space. Such increased soluble Ab and oligomeric
proto-amyloid fragments are considered a likely contributory
factor in the cognitive decline of Alzheimer’s disease patients [15].
Similar processes might contribute to the clinical disease seen in
the anchorless PrP scrapie model. Since all these diseases with
CAA show amyloid localization with basement membranes, drugs
capable of blocking amyloid-basement membrane interactions
might be effective treatments for some of these diseases. In the case
of prion diseases, one such compound, pentosan polysulfate, a
small GAG oligomer, was effective in blocking PrPres generation
in an infected cell line [48] and delayed onset of clinical scrapie in
vivo [41] [42] [44]. Similarly a decoy molecule preventing PrP
interaction with the laminin receptor (LRP/LR) reduced PrPres
levels and delayed disease in vivo [37]. Determining the precise
glycans and proteins involved in the protein interactions leading to
amyloid deposition in all the CAA diseases might be important in
designing new therapeutic approaches.
Methods
Mice
Ethics statement: All mice were housed at the Rocky Mountain
Laboratories (RML) in an AAALAC-accredited facility, and
research protocols and experimentation were approved by the
NIH RML Animal Care and Use Committee.
C57BL/10SnJ mice (Prnp+/+) were obtained from Jackson
Laboratories (Bar Harbor, Maine). C57BL/10SnJ PrP2/2 mice
were created at RML by crossing 129/Ola PrP2/2 mice [49]
with C57BL/10SnJ mice, followed by nine serial backcrosses to
C57BL/10SnJ with selection for the Prnp+/2 genotype using
previously described PCR reactions to detect both the Prnp+ and
Prnp null alleles [19]. One intercross was then done, and C57BL/
10SnJ Prnp2/2 (PrP2/2) mice were selected and interbred.
Heterozygous Prnp+/2 mice were obtained by intercrossing
C57BL/10 (Prnp+/+) mice with C57BL/10 Prnp2/2 mice.
Transgenic GPI anchorless PrP mice (tg44+/2 and tg23+/2)
were made as described previously [19] and then backcrossed to
C57BL/10SnJ-Prnp2/2 mice for six to nine generations with
selection for the Prnp2/2 genotype and the tg44 or 23+/2
genotype. Thus these mice contained one anchorless PrP
transgene allele and did not express any normal anchored mouse
PrP allele. Heterozygous transgene lines tg23+/2 and tg44+/2
were each interbred to create homozygous lines (tg44+/+ and
Box 1. Three neuropathogenic processes
found in scrapie-infected homozygous
anchorless PrP transgenic mice (tg44+/+ and
tg23+/+).
1. Displacement of brain structure by rapidly expanding
amyloid plaques
N Associated with neuronal dropout and adjacent axonal
and neurite damage
2. Early PrPres amyloid on or within basement membranes
of endothelial cells, smooth muscle cells and pericytes
N Possible damage to basement membrane and ob-
struction of the flow of interstitial brain fluid by PrPres
amyloid
N Possible role of basement membrane components in
assisting PrPres formation, e.g. glucosaminoglycans,
collagen, laminin, etc.
N Vascular occlusion and occasional micro-hemorrhages
3. Accumulation of PrPres in the interstitial space between
neurite and glial processes
N Neuronal and glial toxicity with formation of swollen
neurites and glial processes with fewer organelles
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time DNA PCR on an ABI Prism 7900 HT Sequence detection
system and SDS 2.2.2 software. The following probes and primers
were designed to amplify the mouse Prnp sequence: probe
(moPrPlower418T): (59-CGGTCCTCCCAGTCGTTGCCAAA),
forward primer (moPrP-396F): (59-CGTGAGCAGGCCCAT-
GATC), reverse primer (moPrP-465R): (59GCGGTACATGT-
TTTCACGGTAGT). Individual mice identified by rtPCR as
transgene homozygous were then bred to Prnp2/2 mice to
confirm homozygosity. Homozygous mice were then interbred to
create additional mice for experimentation. Both tg44 and tg23
lines were used in the present experiments to demonstrate that the
observed findings were consistent with transgene expression rather
than a result of an integration site artifact.
Scrapie infections
Four to six week old mice were inoculated intracerebrally with
50 ml of a 1% brain homogenate of 22L or RML scrapie
containing 0.7–1.0610
6 ID50. One ID50 is the dose causing
infection in 50% of C57BL/10 mice. Animals were observed daily
for onset and progression of scrapie. Mice were euthanized when
clinical signs were consistent and progressive. Signs differed
somewhat in C57BL/10 and tg44+/+ and tg23+/+ mice (Table 1).
In heterozygous tg44+/2 and tg23+/2 mice many mice
developed signs of debilitation such as weight loss, dermatitis
and infections requiring euthanasia prior to severe neurological
signs.
Immunoblotting
For detection of PrPsen from uninfected brains, tissues were
homogenized (20% w/v) using a bead beater in ice-cold 0.01 M
Tris-HCl pH 7.6 containing protease inhibitors (10 mM leupeptin,
1 mM pepstatin, and 1 mM aprotinin). Each sample was vortexed
for 1 minute followed by sonication for 1 minute. Insoluble debris
was removed by centrifugation at 2700 g for 10 minutes at 4uC.
Samples were mixed 1:1 with 2X SDS-PAGE sample buffer and
boiled for 3–5 minutes. PNGase F reactions were done using
4.4 mg tissue equivalents in a total volume of 20 ml SDS-PAGE
sample buffer [50]. Samples were serially diluted two-fold in
sample buffer to give the amount of brain tissue (mg brain
equivalents) indicated for each lane. Immunoblots were probed by
using monoclonal anti-PrP D13 at a dilution of 1:5000 (InPro
Biotechnology, South San Francisco, CA), followed by secondary
antibody sheep anti-human Ig (dilution 1:5000) (GE Healthcare,
formerly Amersham Biosciences, Piscataway, NJ) and enhanced
chemiluminescence according to the manufacturers instructions
(Amersham-Pharmacia, Uppsala, Sweden).
For detection of PrPres either with or without PNGase F,
samples were prepared as described [51]. Blots were probed as
described above.
Brain grafting
Embryonic brain tissue was obtained from E12–E14 C57BL/6
embryos which expressed green fluorescent protein (GFP) in all
tissues [25]. Mice were purchased originally from Jackson
laboratories and were bred at Rocky Mountain Laboratories by
Dr. Kim Hasenkrug. Pregnant mothers were euthanized and
embryos dissected with forceps in media under a dissecting
microscope to obtain the mesencephalon and telencephalon.
Tissue was partially disrupted by pipetting to generate small
fragments. This suspension (30 ml) was inoculated intracerebrally
through the skull into the parietal brain region of 3–4 week old
PrPnull mice or tg44+/2 mice. One month later recipient mice
were infected intracerebrally with 22L scrapie as described above.
At various times thereafter mice were euthanized and brain tissue
was examined histologically for GFP and PrPres by specific
immunohistochemistry and for typical scrapie-induced gray matter
spongiosis by H&E staining.
Histopathology and immunohistochemistry
Mice were euthanized and brains were placed in 3.7%
phosphate-buffered formalin for 3 to 5 days before dehydration
and embedding in paraffin. Serial 4 mm sections were cut using a
standard Leica microtome, placed on positively charged glass
slides and dried overnight at 56uC. Slides were stained with a
standard protocol of hematoxylin and eosin (H&E) for observation
of overall pathology. For PrPres detection, slides were rehydrated
in 0.1 M citrate buffer, pH 6.0 and then heated at 120uC, 20 psi
for 20 minutes in a decloaking chamber (Biocare, Walnut Creek,
CA). Immunohistochemical staining was performed using the
Ventana automated Nexus stainer (Ventana, Tucson, AZ).
Staining for PrP used a standard avidin-biotin complex immuno-
peroxidase protocol using anti-PrP antibody D13 (In-Pro Biotech-
nology, South San Francisco, CA) at a dilution of 1:500 and
incubated at 4uC for 16 hours. Biotinylated goat anti-human IgG
(Jackson Immuno Research, West Grove, PA) was used at a 1:500
dilution as the secondary antibody. Detection was performed with
Ventana streptavidin-alkaline phosphatase with Fast Red chro-
mogen. Tissue sections for microglia staining were pretreated and
stained with anti-Iba1 as described [52] except that detection was
done using the Ventana Fast Red chromagen as above. Astroglia
were stained with anti-GFAP as described [52], and detection was
completed with Ventana streptavidin-alkaline phosphatase using
Fast Red. Tissue sections for staining with anti-amyloid precursor
protein (APP) were pretreated as described for anti-PrP antibody
D13. Anti-APP (Zymed Laboratories, San Francisco, CA) was
used at a 1:500 dilution followed by a 1:250 dilution of
biotinylated-goat anti-rabbit IgG (Vector Laboratories, Burling-
ton, CA), and detection with Ventana streptavidin-horseradish
peroxidase plus amino ethyl carbazol (AEC) chromagen. Staining
of phosphorylated neurofilament proteins was performed using a
monoclonal antibody cocktail pan-axonal neurofilament marker
SMI-312 (Covance, Princeton, NJ) at a 1:250 dilution. Monoclo-
nal antibody to nonphosphorylated neurofilament proteins was
also used (SMI-311). Primary antibodies were followed by
biotinylated horse anti-mouse IgG secondary antibody at a
1:250 dilution. Ventana AEC reagent was used for detection.
Green fluorescent protein (GFP) was detected using a mixture of
two mouse anti-GFP monoclonal antibodies (clones 7.1 and 13.1)
at dilution of 1:200 (Roche Applied Science, Indianapolis, IN),
followed by biotinylated horse anti-mouse IgG (Vector Laborato-
ries, Burlington, CA) at a dilution of 1:250 and detected with AEC
chromogen (Ventana) as described above. All histopathology slides
were read using an Olympus BX51 microscope and images were
obtained using Microsuite FIVE software.
Perfusion/Processing for electron microscopy
Mice were perfused with fixative containing 3% paraformalde-
hyde and 1% glutaraldehyde in PBS. Excised tissues were then
immersed in this fixative and held overnight at 4 degrees C. Tissue
pieces were processed further using a LynxH automated tissue
processor with agitation as follows: one wash in PBS for 3 hr at 20
degrees, one wash in 0.1 M sodium phosphate buffer pH 7.2 at 20
degrees for 4 hr, post-fix in 2% osmium tetroxide in phosphate
buffer at 20 degrees for 6 hr, one wash in phosphate buffer at 20
degrees for 3 hr, three washes in water at 20 degrees for 3 hr each,
in-block staining with 1% uranyl acetate in water at 20 degrees for
6 hr, 3 washes in water at 20 degrees for 3 hr each, dehydration in
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infiltration at 20 degrees in Araldite resin (Structure Probe, Inc.,
West Chester, PA) at 50% for 8 hr, 75% for 12 hr, and two
changes of 100% for 20 hr each. Further tissue blocks were
processed using a Leica EM TP processor using the procedure
above with the omission of the uranyl acetate. Tissue blocks were
then transferred to fresh resin in molds and polymerized at 65
degrees for 24 to 48 hr.
Immunolabelling of resin block sections for light
microscopy
Thick (1 mm) sections were stained by toluidine blue or were
immunolabelled using the avidin-biotin technique. Sections were
deplasticized with saturated sodium ethoxide for up to 30 minutes.
Endogenous peroxidase was blocked and sections were de-
osmicated with 6% hydrogen peroxide for 10 minutes, followed
by pre-treatment with neat formic acid for 5 minutes. Normal
serum was then applied for 1 hour to block non-specific labeling.
1A8 anti-PrP serum [53] at a dilution of 1:6000, or pre-immune
serum were then applied for 15 hours and reaction product
developed using 3-39 diaminobenzidine.
Immunolabeling for electron microscopy
For routine electron microscopy areas were selected from 1 mm
thick toluidine blue stained sections and counterstained with
uranyl acetate and lead citrate. For ultrastructural immunohisto-
chemistry, serial 65 nm sections were taken from blocks previously
identified from immuno-labeled 1 mm thick sections as described
above. The 65 nm sections were placed on 600 mesh gold grids
and etched in sodium periodate for 60 minutes. Endogenous
peroxidase was blocked and sections de-osmicated with 6%
hydrogen peroxide in water for 10 minutes followed by
enhancement of antigen expression with formic acid for 10
minutes. Residual aldehyde groups were quenched with 0.2 M
glycine in PBS, pH 7.4 for 3 minutes. Preimmune serum or anti-
PrP primary antibody 1A8 [53] or R30 [54] at a 1:500 or 1:1500
dilution respectively in incubation buffer were then applied for
15 hours. After rinsing extensively, sections were incubated with
Auroprobe 1 nm colloidal gold diluted 1:50 in incubation buffer
for 2 hours. Sections were then post-fixed with 2.5% glutaralde-
hyde in PBS and labeling enhanced with Goldenhance (Universal
Biologicals, Cambridge, UK) for 10 minutes. Grids were
counterstained with uranyl acetate and lead citrate.
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